Current and forecasted 10-year prevalence and incidence of inflammatory bowel disease in Hong Kong, Japan, and the United States

Figure 1 Crude prevalence and incidence of inflammatory bowel disease, Crohn’s disease, and ulcerative colitis in Hong Kong, Japan, and the United States. A: Crude prevalence in Hong Kong, Japan and the United States; B: Crude incidence in Hong Kong, Japan and the United States. Crude prevalence and incidence in Hong Kong were estimated using one diagnostic code definition. IBD: CD: Crohn’s disease; CDARS: Clinical data analysis and reporting system; Inflammatory bowel disease; JMDC: Japan Medical Data Center; Merative: The Merative™ MarketScan^® (“Merative” previously IBM MarketScan Commercial Claims and Encounters) database; UC: Ulcerative colitis.

Figure 2 Current and forecasted prevalence and incidence of inflammatory bowel disease, Crohn’s disease, and ulcerative colitis in Hong Kong, Japan and the United States. A: Prevalence in Hong Kong, Japan and the United States; B: Incidence in Hong Kong, Japan and the United States. The solid line represents the actual age-standardized prevalence and incidence of inflammatory bowel disease, ulcerative colitis, and Crohn’s disease. The dashed lines indicate forecasted prevalence and incidence with the 95% projection intervals highlighted. Prevalence and incidence were age-standardized using the World Health Organization standard population. IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; CDARS: Clinical data analysis and reporting system; JMDC: Japan Medical Data Center. Merative: The Merative™ MarketScan^® (“Merative” previously IBM MarketScan Commercial Claims and Encounters) database.

Figure 3 Sex-stratified prevalence and incidence of inflammatory bowel disease, Crohn’s disease, and ulcerative colitis in Hong Kong, Japan and the United States. A: Prevalence in Hong Kong, Japan and the United States; B: Incidence in Hong Kong, Japan and the United States. The solid line represents the actual age-standardized prevalence and incidence of inflammatory bowel disease, ulcerative colitis, and Crohn’s disease by sex. The dashed lines indicate forecasted prevalence and incidence with the 95% projection intervals highlighted. Prevalence and incidence were age-standardized using the World Health Organization standard population. IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; CDARS: Clinical data analysis and reporting system; JMDC: Japan Medical Data Center. Merative: The Merative™ MarketScan^® (“Merative” previously IBM MarketScan Commercial Claims and Encounters) database.

Figure 4 Age-stratified prevalence and incidence of inflammatory bowel disease, Crohn’s disease, and ulcerative colitis in Hong Kong, Japan, and the United States. A: Prevalence in Hong Kong, Japan and the United States; B: Incidence in Hong Kong, Japan and the United States. The solid line represents the actual prevalence and incidence of inflammatory bowel disease (IBD), ulcerative colitis (US), and Crohn’s disease (CD) by age. The dashed lines indicate forecasted prevalence and incidence with the 95% projection intervals highlighted. Prevalence and incidence were age-standardized using the World Health Organization standard population. CDARS: Clinical data analysis and reporting system; JMDC: Japan Medical Data Center; Merative: The Merative™ MarketScan^® (“Merative” previously IBM MarketScan Commercial Claims and Encounters) database.